Peter Colabuono - 31 May 2022 Form 4 Insider Report for Checkmate Pharmaceuticals, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 31 May 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 31 May 2022, 10:08:17 UTC
Prior SEC filing: 21 Jun 2021
Next SEC filing: 12 Dec 2024
Source filing: View source filing
Reporting owner signature: /s/ Kleem Chaudhary, attorney-in-fact

Key filing fact

Peter Colabuono filed Form 4 for Checkmate Pharmaceuticals, Inc. on 31 May 2022.

Key facts

This page summarizes Peter Colabuono's Form 4 filing for Checkmate Pharmaceuticals, Inc..
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 31 May 2022, 10:08.

Change

Previous filing in this sequence was filed on 21 Jun 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CMPI transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -10,030
Change %: -100%
Price
Shares after: 0
Date: 31 May 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,030
Exercise price: $6.27
Footnotes: F1

CMPI transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -20,000
Change %: -100%
Price
Shares after: 0
Date: 31 May 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 20,000
Exercise price: $10.95
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Peter Colabuono is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 2 footnotes

Footnote F1

At the effective time of the merger contemplated by the Agreement and Plan of Merger dated April 18, 2022, among Checkmate Pharmaceuticals, Inc. (the "Issuer"), Regeneron Pharmaceuticals, and Scandinavian Acquisition Sub, Inc. (the "Merger"), each option granted by the Issuer to purchase Issuer Common Stock, whether or not vested, which has a per share exercise price that is less than $10.50 (each, an "In the Money Issuer Option") that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the total number of Issuer Common Stock subject to such In the Money Issuer Option and (2) the excess of $10.50 over the exercise price of such In the Money Issuer Option, subject to any required withholding of taxes.

Footnote F2

At the effective time of the Merger, each option granted by the Issuer to purchase Issuer Common Stock which has a per share exercise price greater than or equal to $10.50 that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled with no consideration payable.